Search results

1197 results

Sorted by Relevance . Sort by Date

  1. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

    Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

  2. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of

  3. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

  4. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

  5. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

  6. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

  7. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

  8. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab

  9. Vortioxetine for treating major depressive episodes (TA367)

    Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults

  10. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

    Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears

  11. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

  12. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

  13. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

  14. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated

  15. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza)

  16. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

  17. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

  18. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

  19. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

  20. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

  21. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)

  22. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

  23. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

  24. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

  25. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure

  26. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  27. Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA620)

    Evidence-based recommendations on olaparib (Lynparza) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a

  28. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

    Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults

  29. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

  30. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant

  31. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema

  32. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

  33. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

  34. Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

    Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein

  35. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

  36. Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

    Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery for adults with early breast cancer